Natural History of Patients with PH3 and History of Stone Events

  • Research type

    Research Study

  • Full title

    A Natural History Study of Patients with Genetically Confirmed Primary Hyperoxaluria Type 3 with a History of Stone Events

  • IRAS ID

    289642

  • Contact name

    Kerry Russell

  • Contact email

    krussell@dicerna.com

  • Sponsor organisation

    Dicerna Pharmaceuticals Inc

  • Clinicaltrials.gov Identifier

    NCT04542590

  • Clinicaltrials.gov Identifier

    n/a, n/a

  • Duration of Study in the UK

    2 years, 8 months, 2 days

  • Research summary

    Participants in this study have Primary Hyperoxaluria Type 3 (PH3). This is an inherited disease where lack of function of a particular liver enzyme causes the body to accumulate excess amounts of a substance called oxalate. Oxalate leads to a build-up of insoluble calcium salts in the kidneys. People with PH3 are at increased risk for developing kidney stones. Symptoms can develop at any time from infancy to adulthood. Most individuals are diagnosed with PH3 in childhood or early adulthood. Affected individuals may develop kidney stones at any age, and sometimes by the age of 5 years. Kidney function can be impacted by frequent kidney stones. Over time kidney function may become compromised from frequent stones and/or too much calcium deposited in the kidneys, resulting in chronic kidney disease.
    Currently there is no approved therapy for the treatment of patients with PH3. Supportive therapies, such as drinking plenty of water and dietary restrictions of foods high in oxalate, are used to help lower oxalate levels and inhibit the formation of kidney stones.

    No study drug or other experimental treatment/procedures will be administered. This is an observational study requiring urine collection and kidney ultrasound in order to collect data on the rate of new stone formation and the degree of excess calcium in the kidneys to explore the potential relationship between levels of oxalate in the kidneys and new stone formation. This will be beneficial for increasing understanding of the course of PH3 and potentially help to create new therapies for this disease.

  • REC name

    South West - Cornwall & Plymouth Research Ethics Committee

  • REC reference

    20/SW/0191

  • Date of REC Opinion

    18 Feb 2021

  • REC opinion

    Further Information Favourable Opinion